The hepatitis C drug-marketing battle is heating up.
This morning, Abbvie (ABBV)
disclosed positive results from the remaining phase III studies of its
all-oral hepatitis C regimen and said regulatory submissions would begin
early in the second quarter. That’s new and faster regulatory filing
guidance and implies a commercial launch in the fourth quarter of this
year, or perhaps sooner if FDA moves quickly to approve. [Abbvie’s
regimen has Breakthrough Therapy status.]